Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on the pulmonary arterial hypertension market provides an in-depth analysis of segments and sub-segments in the global as well as regional pulmonary arterial hypertension market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional pulmonary arterial hypertension market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global pulmonary arterial hypertension market. According to the report, the global pulmonary arterial hypertension market is projected to grow at a CAGR of 6% over the forecast period of 2021-2027. The Pulmonary arterial hypertension market was valued at USD 7 billion in 2021 and is expected to reach USD 10 billion in 2027.
Pulmonary arterial hypertension is a group of rare and life-threatening diseases that results in increased pulmonary blood pressure and localized hypertension, which may lead to heart disease. The increasing prevalence of pulmonary arterial hypertension, government support for the expansion of orphan drugs, and therefore the growing geriatric population is boosting the expansion of the pulmonary arterial hypertension market. The manifestation of pulmonary arterial hypertension includes breath problems during workouts, chest pain, and blackout. The growth within the number of geriatrics results in consequences which in several cases include complications associated with pulmonary arterial hypertension. The technological advancements are steadily focusing upon the identification of recent molecular pathways which contributes to the event of higher treatments possible over the forecast period.
Major driving factors for the growth of the global pulmonary arterial hypertension market are the change in the standard of living, the growing aged population, and the rising prevalence of pulmonary arterial hypertension. The prevalence of pulmonary arterial hypertension has increased globally from 88 to 115 cases per 1,00,000 population. Numerous Government and private sector initiatives such as the rare disease act and the orphan drug act that create awareness and offer incentives such as tax waivers, credits, assistance & support are anticipated to boost the growth of the global pulmonary arterial hypertension market in the forecast period. However, discontinuing of medicine manufacturing by major players during clinical trials and stringent regulations by the government, lack of awareness about the presence of pulmonary arterial hypertension in the patients, and high diagnosis and healing costs are expected to restrain the market growth in the forecast period. Technological enhancements like biomarkers and new gene therapy for the treatment and advanced oral drugs create an opportunity for the market.
Based on the regions, North America holds the biggest market share of the Pulmonary Arterial Hypertension Market. The increasing number of patients, growing investments in R&D activities, and thus the establishment of technically advanced research centers will contribute to the Pulmonary Arterial Hypertension Market growth within the region. Moreover, the rising frequency of chronic disease is also anticipated to boost the growth of the market. Moreover, various pharma companies and biological organizations are focusing on developing in the Asia Pacific and administering Research and Development activities because of the high population in countries such as India and China. Growing government investment in research and development will boost the growth of the global Pulmonary Arterial Hypertension Market in the Asia Pacific region. Europe region held 10% of the revenue share of the global market in 2020 and is expected to cross USD 194 million in the forecast period. The increase in the prevalence of pulmonary arterial hypertension, ideal workforce, and supportive government regulations will boost the growth of the European region.
The report on the global pulmonary arterial hypertension market covers segments such as drug type, route of administration, and distribution channel. On the basis of drug type, the sub-markets include prostacyclin and prostacyclin analogs, soluble guanylate cyclase stimulators, endothelin receptor antagonists, phosphodiesterase 5, calcium channel blockers, and others. On the basis of route of administration, the sub-markets include oral, and injectable. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, online pharmacies, and others.
The report provides profiles of the companies in the market such as Bayer HealthCare AG, Arena Pharmaceuticals, Pfizer Inc., Actelion Pharmaceuticals Ltd, AstraZeneca, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., GlaxoSmithKline Plc. (GSK), Novartis International AG, and United Therapeutics Corporation.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of pulmonary arterial hypertension. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.